GB2400033A - Use of fluoroquinolone antibiotics for the treatment of Q fever - Google Patents
Use of fluoroquinolone antibiotics for the treatment of Q fever Download PDFInfo
- Publication number
- GB2400033A GB2400033A GB0307262A GB0307262A GB2400033A GB 2400033 A GB2400033 A GB 2400033A GB 0307262 A GB0307262 A GB 0307262A GB 0307262 A GB0307262 A GB 0307262A GB 2400033 A GB2400033 A GB 2400033A
- Authority
- GB
- United Kingdom
- Prior art keywords
- group
- hydrogen atom
- cal
- compound
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010037688 Q fever Diseases 0.000 title claims abstract description 26
- 238000011282 treatment Methods 0.000 title claims abstract description 26
- 229940124307 fluoroquinolone Drugs 0.000 title description 13
- 239000003242 anti bacterial agent Substances 0.000 title description 7
- 229940088710 antibiotic agent Drugs 0.000 title description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 40
- 150000001875 compounds Chemical class 0.000 claims abstract description 36
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- 125000004103 aminoalkyl group Chemical group 0.000 claims abstract description 13
- 125000003277 amino group Chemical group 0.000 claims abstract description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 7
- 201000010099 disease Diseases 0.000 claims abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 4
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 208000034712 Rickettsia Infections Diseases 0.000 claims description 13
- 206010061495 Rickettsiosis Diseases 0.000 claims description 13
- 125000003342 alkenyl group Chemical group 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 13
- 125000000304 alkynyl group Chemical group 0.000 claims description 13
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 description 24
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 10
- 230000003115 biocidal effect Effects 0.000 description 8
- -1 oflaxacin Chemical compound 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 7
- 229960003923 gatifloxacin Drugs 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 6
- 229960003722 doxycycline Drugs 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 229960003405 ciprofloxacin Drugs 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 210000001325 yolk sac Anatomy 0.000 description 4
- AIJTTZAVMXIJGM-UHFFFAOYSA-N Grepafloxacin Chemical compound C1CNC(C)CN1C(C(=C1C)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 AIJTTZAVMXIJGM-UHFFFAOYSA-N 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229960003170 gemifloxacin Drugs 0.000 description 3
- ZRCVYEYHRGVLOC-HYARGMPZSA-N gemifloxacin Chemical compound C1C(CN)C(=N/OC)/CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 ZRCVYEYHRGVLOC-HYARGMPZSA-N 0.000 description 3
- 229960000642 grepafloxacin Drugs 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 238000004626 scanning electron microscopy Methods 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 241000606701 Rickettsia Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229960003702 moxifloxacin Drugs 0.000 description 2
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 2
- 229960004236 pefloxacin Drugs 0.000 description 2
- FHFYDNQZQSQIAI-UHFFFAOYSA-N pefloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 FHFYDNQZQSQIAI-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000002135 phase contrast microscopy Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000012809 post-inoculation Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000004627 transmission electron microscopy Methods 0.000 description 2
- 229960000497 trovafloxacin Drugs 0.000 description 2
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920003319 Araldite® Polymers 0.000 description 1
- 206010003757 Atypical pneumonia Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241001445332 Coxiella <snail> Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical class BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- JEJBBWQXAMSBQT-UHFFFAOYSA-N butanedioic acid;propanoic acid Chemical compound CCC(O)=O.OC(=O)CCC(O)=O JEJBBWQXAMSBQT-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- BALGDZWGNCXXES-UHFFFAOYSA-N cyclopentane;propanoic acid Chemical compound CCC(O)=O.C1CCCC1 BALGDZWGNCXXES-UHFFFAOYSA-N 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000001659 ion-beam spectroscopy Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000001937 non-anti-biotic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 150000002923 oximes Chemical group 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960004954 sparfloxacin Drugs 0.000 description 1
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940072172 tetracycline antibiotic Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- DNYWZCXLKNTFFI-UHFFFAOYSA-N uranium Chemical class [U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U] DNYWZCXLKNTFFI-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Use of a compound of formula (I) in the treatment of Q fever and related diseases: <EMI ID=1.1 HE=46 WI=109 LX=522 LY=782 TI=CF> <PC>in which R<1> is a hydrogen atom or a C1-C6 alkyl group, R<2> is a hydrogen atom or a C1-C6 alkoxy group and R<3> is a C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl group or salt thereof. Alternatively, the use of a compound of formula (II) in the treatment of Q fever and related diseases: <EMI ID=1.2 HE=47 WI=114 LX=481 LY=1771 TI=CF> <PC>in which R<1> is a hydrogen atom or a C1-C6 alkyl group, R<2> is a hydroxyl group, a C1-C6 alkoxy group or an amino group, and R<3> is a is a hydrogen atom, a C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, C1-C6 aminoalkyl group or salt thereof.
Description
USE OF FLUOROQUINOLONE ANTIBIOTICS FOR THE TREATMENT OF
Q FEVER.
The present invention is generally concerned with the use of certain fluoroquinolones for the treatment of Q fever.
Q fever is a zoonosis, which is endemic throughout the world. The infectious organism, the rikettsia Coxiella burnetti, (C. burnetti) is an obligate intracellular bacterium found in lice and ticks. Infection in humans, by bite, can be asymptomatic, acute or chronic. Acute Q fever is often associated with atypical pneumonia whilst chronic Q fever often manifests as endocarditis.
C. burnetti has been shown to be susceptible to tetracycline antibiotics, in particular, doxycycline, which form the basis of present treatment of Q fever. A number of recent studies have focused on the possible use of fluoroquinolone antibiotics, which are known to have broad spectrum activity, for the treatment of Q fever and infection by other rickettsia. In particular, so called first generation fluoroquinolones, ofloxacin and pefloxacin have been shown to be effective against C. burnetti in ovo (D. Raoult et al., Antimicrobial Agents and Chemotherapy, 1989, 33, 621-623). First generation fluoroquinolones ciprofloxacin, sparfloxacin, oflaxacin, pefloxacin and levofloxacin have been shown as bacteriostatic at concentrations of 0.5 to 1.0 mg/1 against C. burnetti (Nine Mile strain) in L929 cells (idem, ibid, 1991, 35, 88-91 and 2070-2077; Journal of Antimicrobial Chemotherapy, 1991, 39, 725-730). More recently, minimum inhibitory concentration (MIC) values of 0.5 to 1.0 mg/1 have been reported for the second generation fluoroquinolone, moxifloxacin against acute and chronic disease causing strains of C. burnetti (idem, Antimicrobial Agents and Chemotherapy, 2001, 45, 301-302). In addition a MIC value of 1.0 mg/1 has been reported for trovafloxacin against C. burnetti.
The present invention has found that certain second generation, fluoroquinolones have surprising efficacy against C. burnetti. In particular, it has been surprisingly found to that gatifloxacin is 20 times more effective than ciprofloxacin and ten times more effective than other second generation fluoroquinolones. Further, the efficacy of gatifloxacin approaches that of doxycycline.
The surprising efficacy of these fluoroquinolones offers increased possibilities for the effective treatment of Q fever and other rickettsia infections including the treatment of patients in whom doxycycline or other treatment is contraindicated. Further, they reduce the possibility of doxycycline resistant strains whilst offering alternative treatments therefor or in times of high demand.
The present invention generally aims to provide an alternative, effective treatment of Q fever and other rickettsia infections. The present invention also aims to provide fluoroquinolones suitable for the effective treatment of Q fever and other rickettsia infections.
Accordingly, in one aspect, the present invention provides compounds of formula (I) Rl o (I) in which Ret is hydrogen atom or a Cal to C6 alkyl group, R2 is a hydrogen atom or a Cat to C6 alkoxy group, and R3 is a Cat to C6 alkyl, Cat to C6 alkenyl or C' to C6 alkynyl group or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of Q fever and other rickettsia diseases.
As used herein the term "C' to C6 alkyl" refers to a branched or straight chain alkyl group having 1 to 6 carbon atoms. Examples include methyl, ethyl, propyl, isopropyl, n-butyl, s-butyl, n-pentyl, neopentyl, n-hexyl and the like. Optionally the groups may be substituted by simple substituents such as a halogen atom (fluorine, chlorine or bromine). Examples include chloromethyl, dichloromethyl, trichloromethyl, trifluoromethyl and the like.
Further, the term "Cal to C6 alkoxy" is used herein to refer to a ROradical where R is a Cal to C6 alkyl group defined above.
As used herein, the term "Cat to C6 alkenyl" means a branched or straight chain group, substituted or unsubstituted, having 1 to 6 carbon atoms and comprising one or more double carbon-carbon bonds. Examples include ethenyl, 2-propenyl, 1-propenyl and the like.
The term "Cat to C6 alkynyl, as used herein, means a branched or straight chain group, substituted or unsubstituted, having I to 6 carbon atoms and comprising one or more triple carbon-carbon bonds. Examples include ethynyl, 2-propynyl, 1-propynyl and the like.
In one embodiment of the present invention, Ret is a hydrogen atom or a methyl group and R2 is a methoxy group. Preferably, R' is a hydrogen atom.
In an alternative embodiment, Rt is a Cat to C6 alkyl group and R2 is a hydrogen atom.
Preferably Ri is a methyl group.
In either embodiment, R3 is preferably a methyl group. It will be apparent that R3 confers on compounds of the present invention an asymmetrically substituted carbon atom at the three position of the 1- piperazinyl ring. The medicaments or compositions of the present invention may, in particular, comprise a racemate or an optically pure stereoisomer. Preferably, the medicament or composition comprises the stereoisomer in which the asymmetric carbon has an S configuration (as determined by the IUPAC standards).
In one specific embodiment of the present invention, the compound of formula (I) is (+/-)-1 -cyclopropyl-6-fluoro- 1,4-dihydro-8-methoxy-7-(3 -methyl- 1 - piperazinyl)-4 oso-3-quinolinecarboxylic acid. This compound, commonly known as gatifloxacin, is commercially available in the form of the sesquihydrate under the name Tequin_ (Bristol Meyers Squibb, New Jersey, USA).
In an alternative specific embodiment of the present invention, the compound of formula (I) is (S)- 1 -cyclopropyl-6-fluoro- 1,4-dihydro-5methyl-7-(3 -methyl- 1 -piper azinyl)-4-oxo-3-quinoline carboxylic acid. This compound, commonly known as grepafloxacin, is commercially available in the form of the hydrochloride salt under the name Raxar_ (Bayer, UK).
In a second aspect, the present invention provides a method of treatment for Q fever and other rickettsia infections comprising the step of administering to a patient in need thereof a pharmaceutically effective amount of a compound of formula (I)
D I
TO r ' J R7 (I) in which R' is hydrogen atom or a Cal to C6 alkyl group, R2 is a hydrogen atom or a C' to C6 alkoxy group, and R3 is a Cal to C6 alkyl, Cat to C6 alkenyl or Cal to C6 alkynyl group or a pharmaceutically acceptable salt thereof.
It is preferred that the method comprises administering a dose of between I mg to 1000 mg of the compound of formula (I) daily. Preferably, the method comprises administering a dose of between 1 to 500 mg daily. Most preferably, the method comprises administering gatifloxacin in a dose of 1 to 500 mg daily.
In a third aspect, the present invention provides a pharmaceutical composition for use in the treatment of Q fever and other rickettsia infections comprising a compound of formula (I) A\ O 3: (I) in which R' is hydrogen atom or a Cal to C6 alkyl group, R2 is a hydrogen atom or a C' to C6 alkoxy group, and R3 is a Cat to C6 alkyl, Cal to C6 alkenyl or Cat to C6 alkynyl group or a pharmaceutically acceptable salt thereof.
The medicarnents or compositions of the present invention may comprise a combination of more than one compound formula (I). Alternatively, compounds of formula (I) may be administered as medicaments or compositions formulated for simultaneous or sequential use thereof. The medicaments or compositions may also comprise a compound of formula (I) and another active agent, such as doxycycline, known for the treatment of Q fever and other rickettsia infections.
The medicaments or compositions of the present invention may comprise a compound of formula (I) in zwitterionic form or in the form of a pharmaceutically acceptable salt. Suitable salts include salts of organic acids, for example acetate, adipate, alginate, aspartate, benzoate, benzene sulphonate, bisulphate, butyrate, camphorate, camphor sulphonate, citrate, carbonate, digluconate, cyclopentane propionate, dodecylsulphate, ethane sulphonate, glucoheptanoate, glycerophosphate, hemisulphate, heptanoate, hexanoate, fumarate, 2-hydroxyethane sulphonate, lactate, maleate, methane sulphonate, nicotinate, 2-napthalene sulphonate, oxalate, palmoate, pectinate, persulphate, 3-phenylpropionate, picrate, pivalate, propionate succinate, tartrate, thiocyanate, p-toluene sulphonate, and salts of inorganic acids such as hydrochloride, hydrobromide, hydroiodide, sulphate, phosphate.
Pharmaceutically acceptable salts may also comprise cations based on the alkali or alkaline earth metals such as sodium, lithium, potassium, calcium, magnesium, aluminium and the like. In addition they may include salts formed by quaternisation of suitable basic nitrogen containing groups with short chain alkyl halides such as methyl, ethyl, propyl and butyl chlorides, bromides or iodides or long chain alkyl halides such as decyl, lauryl, myristyl, and stearyl chlorides, bromides or iodides.
Further, such salts may also be formed from dialkyl sulphonates such as dimethyl, diethyl, dibutyl or diamyl sulphates or from aralkyl halides such as benzyl bromides and the like.
The medicaments or compositions of the present invention may be administered orally, parenterally, sublingually, by inhalation, rectally or topically. They may comprise dosage formulations containing conventional pharmaceutical carriers, adjuvants and other vehicles as desired. Topical administration may involve the use of transdermal patches or ionospheresis devices. The term "parenteral" as used herein includes subcutaneous injection, intravenous, intramuscular, intrasternal injection or infusion techniques. The choice of the method of administration will depend on a number of factors including the nature of the formulation, the strain of the bacterium, the manifestation and severity of the infection, the patient and the like.
It is preferred that the medicament or composition of the present invention is in solid dosage form although liquid dosage forms may also be used. Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms the fluoroquinolone may be admixed with at least one inert diluent such as sucrose, lactose or starch or mixtures thereof. The dosage forms may also comprise, in accordance with normal practice, additional substances such as lubricating agents, for example, magnesium stearate. For capsules, tablets and pills the dosage forms may also comprise buffer agents. Tablets and pills may also be prepared with enteric coatings.
Liquid dosage forms for oral administration may comprise pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs containing such inert diluents as are common to the art. Such dosage forms may also comprise adjuvants such as wetting agents, emulsifying and suspending agents as well as sweetening, flavour and/or perfume agents.
Injectable preparations may be formulated in accordance with the known art using suitable dispersing or wetting agents and suspending agents. The preparation may be formulated as a sterile injectable solution or suspension in a parenterally acceptable diluent or solvent, for example, as a solution in propanedioVwater (1:3). Acceptable vehicles and solutions include Ringer's solution and isotonic sodium chloride..
Sterile fixed oils, including synthetic mono- or all-glycerides may also be employed as a solvent or suspending medium. Injectable preparations may also include fatty acids, such as oleic acid.
The medicaments and pharmaceutical compositions of the present invention may also include other ingredients necessary to achieve optimum formulation, for example, preservatives, stabilisers, excipients and natural or synthetic lecithins. They may also comprise liposomes derived, for example, from phospholipids or other lipid substances. The liposomes may comprise multi-lamellar, hydrated liquid crystals dispersed in an aqueous medium. Any pharmaceutically acceptable and metabolisable lipid capable of forming liposomes may be used.
In a fourth aspect the present invention provides use of a compound of formula (II) \ R. (II) in which Rat is hydrogen atom or a C' to C6 alkyl group, R2 is a hydroxyl group, a Cal to C6 alkoxy group or an amino group, and R3 is a hydrogen atom or a Cat to C6 alkyl, Cat to C6 alkenyl, Cal to C6 alkynyl, or C' to C6 aminoalkyl group or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of Q fever and other rickettsia infections.
As used herein the term Cal to C6 aminoalkyl refers to a straight or branched carbon chain radical, having 1 to 6 carbon atoms, in which the terminal part is the amino radical -NR4R5, in which R4 and R5 independently are a hydrogen atom, a Cat to C6 alkyl group or a Cat to C6 ester group.
In a preferred embodiment, R' is a hydrogen atom and R2 is a methoxy group. In this embodiment R3 is preferably a Cal to C6 aminoalkyl group. Still more preferably, the aminoalkyl group is a Cat aminoalkyl and R4 and R5 are both hydrogen atoms.
It will be apparent that compounds according to the fourth aspect of the present invention comprise an asymmetrically substituted carbon atom at the 3 position of the pyrolidinyl ring. In addition the oxime moiety on the pyrolidinyl ring can lead to E, Z diastereoisomers or mixtures thereof. The medicaments or compositions of the present invention may therefore comprise a mixture of stereoisomers and in particular 15, a racemate of E, Z diastereoisomers or a racemate of a single E or Z diastereoisomer.
Preferably, the medicaments or compositions comprise a single optically pure stereoisomer. Still more preferably, the medicaments or compositions comprise an optically pure Z stereosiomer in which the asymmetric carbon atom has a S configuration (as determined by the IUPAC standards).
In one specific embodiment of the present invention, the compound of formula (II) is (+/-) 7-[3-(aminomethyl)-4-oxo- 1 -pyrolidinyl]- 1 -cyclopropyl-6-fluoro- 1,4-dihydro-4- oxo-1,8-napththyridine-3-carboxylic acid, 74-(Z)-(O-methyloxime). This compound, commonly known as gemifloxacin, is commercially available under the trade name FactiveTM (Smith Kline Beecham, UK) as a mesylate salt.
In a fifth aspect the present invention provides a method of treatment of Q fever and other rickettsia infections comprising the step of administering to a patient in need thereof a pharmaceutically effective amount of a compound of formula (II) Al R\ MEL R3 (II) in which Ret is hydrogen atom or a Cal to C6 alkyl group, R2 is a hydroxyl group, a Cat to C6 alkoxy group or an amino group, and R3 is a hydrogen atom or a Cal to C6 alkyl, Cal to C6 alkenyl, Cal to C6 alkynyl Cat to C6 aminoalkyl group or a pharmaceutically acceptable salt thereof.
In a sixth aspect, the present invention provides for a pharmaceutical composition for the treatment of Q fever and other rickettsia infections comprising a pharmaceutically effective amount of a compound of formula (II) R. (II) in which R' is hydrogen atom or a Cal to C6 alkyl group, R2 is a hydroxyl group, a C' to C6 alkoxy group or an amino group, and R3 is a hydrogen atom or a Cal to C6 alkyl, Cat to C6 alkenyl, Cal to C6 alkynyl or Cal to C6 arninoalkyl group or a pharmaceutically acceptable salt thereof.
It will be understood that the medicaments or compositions of the present invention comprising compounds of formula (II) may be formulated or used as described for compounds of formula (I).
The present invention is illustrated by reference to the following examples: Materials and Methods C. burnetti strain Nine Mile, a strain associated with acute Q fever in humans, was obtained from the American Type Culture Collection (ATCC) and inoculated into yolk sacs of 6 day old embryonated hen eggs under the Association for Classifiation of Dangerous Pathogens (ACDP) containment level 3 conditions. When 50% mortality had occurred (9 days post inoculation), yolk sacs from surviving eggs were harvested. The yolk sacs were homogenized in sterile phosphate buffered saline (PBS, pH 7.4) and pooled to create a 30% v/v homogenate stock. All stocks were aliquoted and frozen at-70 C.
Tissue culture flasks (12.5 cm2) were primed with 4.5 ml of Vero cells suspended in Leibovitz (L15) growth medium (Gibco Lid), with 5% foetal calf serum (FCS) at 5.0 x 105 cells per ml. The mixture was incubated overnight at 37 C to achieve confluent cell growth. The incubation medium was then replaced with 200,ul of C. burnetti containing yolk sac homogenate at 10- dilution in sterile PBS. After incubation for lh at 37 C, the inoculum was removed and the cells were twice washed with 4.0 ml PBS. A L15 medium (2% FCS) was added and the flasks incubated at 37 C for 10 mine prior to assay.
Similar control flasks were prepared except that the inoculation step was omitted or a non-infected egg homogenate was used.
An immunofluorescent assay (IFA, Maurin et al., Journal of Antimicrobial Chemotherapy, 1997, 45, 301-302) was used to confirm that the cells had become enlarged through incorporation of C. burnetti. The monolayer of cells was broken up by the addition of 1% trypsin-EDTA. Aliquots of the resulting suspension (501) were dotted on microscope slides, excess liquid removed after lOs and the cells air dried and fixed in acetone (at -20 C) for 10 mine. Rabbit anti-C. burnetti serum was added to the cells at 1/100 dilution PBS and incubated at 37 C for lh. After washing three times in PBS, goat anti-rabbit immunoglobulin (Sigma, UK) was added at 1/1000 dilution in PBS with Evans blue and incubated at 37 C for Ih. The cells were subsequently viewed using fluorescent microscopy.
Extracellular C. burnetti was detected in culture supernatants from flasks inoculated with 10- dilution of stock 3 days post inoculation. Intracellular C. burnetti was detected only from day 4 onwards.
Condonation of infection of the cells was also confirmed using scanning and transmission electron microscopy. Glutaraldehyde (I ml of a 2.5% solution w/v) was added to each flask and the mixture incubated at 37 C for 30 mine. After removal of the supernatant the cell sheet was scaped off and suspended in I ml of a 2.5% glutaraldehyde solution for 4 h at 48OC. The cells were pelleted by gentle centrifugation (500 g for 15 mine.) and resuspended in 0.1 M phosphate buffer (pH 7.0) at room temperature for 4 h. Samples were post fixed in 1% osmium tetroxide in phosphate buffer (pH 7.0) at room temperature for 4 h. The cells were then dehydrated through a graded ethanol series and embedded in araldite resin. Ultra-thin sections of the impregnated resin were prepared, stained with uranium and lead salts and examined under a Phillips CM100 transmission electron microscope operating at 80kV.
Scanning electron microscopy was performed by fixation of cells grown as before in shell vials containing 2 ml L15 media (Gipco Ltd). The cells were fixed and dehydrated as described before and air dried with hexamethyldisilazane. The cells were mounted on SEM stubs, coated with gold by ion beam sputtering and examined under a Phillips XL30FEG scanning electron microscope.
Enlarged rounded Vero cells were observed 8 days post infection using scanning electron microscopy. Transmission electron microscopy confirmed intracellular C. burnetti.
Stock solutions (lmg/ml) of antibiotics, including compounds of the present invention, were prepared in sterile PBS (pH 7.4) and diluted to the required concentration in L15 media (Gibco Ltd) for susceptibility studies.
Antibiotic susceptibility was examined by preparing infected cells as described above except that the final step involved the addition of the L15 medium (2% FCS) containing the test antibiotic in concentrations ranging from 0.001 to 8 mg/1 and incubating at 37 C for 6 days.
At 6 days post infection, the flasks were viewed by phase contrast microscopy (Olympus). Enlarged, infected cells were counted using an eyepiece graticule at 100 times magnification, which gave a defined field of view (FV). The number of infected cells was counted per FV. Ten FVs were counted per flask in a set pattern: three FVs across the top, four across the middle and three across the bottom of the flask. A mean number of infected cells per FV was then derived.
Examples 1 to 3 and Comparative Examples The activity of eight antibiotics was determined by inspection of the number of cells compared to controls after addition of a predetermined concentration of antibiotic stock solution using phase contrast microscopy. Table 1 summarises the results obtained with three embodiments of the present invention compared to those obtained for antibiotics known as bacteriostatics for C. bur7etti. The mean number of infected cells in the antibiotic treated groups is expressed in Table 1 as a percentage of infected cells in non- antibiotic treated controls for a particular concentration.
The minimum inhibitory concentration (MIC) of an antibiotic is defined as the lowest antibiotic concentration in the incubation medium which inhibits intracellular growth of C. burnetti (determined by the presence of enlarged cells) to less than or equal to 10% of the antibiotic free control. Each experiment was carried out in duplicate.
As may be seen, gatifloxacin (Compound 3) has a surprising low MIC value (0.1 mg/1) and has the lowest number of infected cells in all concentrations compared to the other fluoroquinolones tested. Thus gatifloxacin is at least 20 times active as ciprofloxacin (2.0 mg/1). Grepafloxacin (Compound 1) and gemifloxacin (Compound 2) have a MIC value (1.0 mg/1) at least two times lower than ciprofloxacin.
Antibiotic Concentration (mall) | 8.0 4.0 2.0 1.0 0.5 0.1 0.05.01.005.00 Doxycycline 0 0 0 0 0 0 25 85 Ciprofloxacin 0 7 41 48 83 90 Trovafloxacin 0 0 23 39 52 Moxifloxacin 0 0 24 42 46 52 Azimthromycin 38 34 16 23 51 39 56 40 Compound 1 0 0 12 29 43 63 (Grepafloxacin) Compound 2 0 2 17 46 59 52 (Gemifloxacin) Compound 3 0 0 2 32 38 27 (Gatifloxacin)
Table 1
Claims (33)
1. Use of a compound of formula (I)
R R3
in which Ret is hydrogen atom or a C' to C6 alkyl group, R2 is a hydrogen atom or a C' to C6 alkoxy group, and R3 is a C, to C6 alkyl, C, to C6 alkenyl, or C, to C6 alkynyl group or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of Q fever and related diseases.
2. Use according to Claim 1, in which Ret is a methyl group and R2 is a methoxy group.
3. Use according to Claim 1, in which Rat is a Cat to C6 alkyl group and R2 is hydrogen atom.
4. Use according to Claim 3, in which R' is a methyl group.
5. Use according to any preceding Claim, in which R3 is a methyl group.
6. Use according to Claim 5, in which the compound is the S stereoisomer.
7. A method of treatment for Q fever and other rickettsia infections comprising the step of administering to a patient in need thereof a pharmaceutically effective amount of a compound of formula (I) OF = LOU (I) in which R' is hydrogen atom or a C, to C6 alkyl group, R2 is a hydrogen atom or a Cal to C6 alkoxy group, and R3 is a C, to C6 alkyl, C, to C6 alkenyl or C, to C6 alkynyl group or a pharmaceutically acceptable salt thereof.
8. A method according to Claim 7, in which R' is a methyl group and R2 is a methoxy group.
9. A method according to Claim 7, in which Ret is a Cal to C6 alkyl group and R2 is hydrogen atom.
10. A method according to Claim 9, in which Ret is a methyl group.
1 1. A method according to any of Claims 7 to 10, in which R3 is a methyl group.
12. A method according to Claim 11, in which the compound is the S stereoisomer.
13. A pharmaceutical composition for use in the treatment of Q fever and other rickettsia infections comprising a compound of formula (I) 81 o F "LR (I) in which R' is hydrogen atom or a C, to C6 alkyl group, R2 is a hydrogen atom or a Cal to C6 alkoxy group, and R3 is a Cal to C6 alkyl, C, to C6 alkenyl or Cal to C6 alkynyl group or a pharmaceutically acceptable salt thereof.
14. A composition according to Claim 13, in which R' is a methyl group and R2 is a methoxy group.
15. A composition according to Claim 13, in which R' is a C, to C6 alkyl group and R2 is hydrogen atom.
16. A composition according to Claim 15, in which Rat is a methyl group.
17. A composition according to any of Claims 13 to 16, in which R3 is a methyl group.
18. A composition according to Claim 17, in which the compound is the S stereoisomer.
19. Use of a compound of formula (II) Rat H R3 (II) in which Ret is hydrogen atom or a C' to C6 alkyl group, R2 is a hydroxyl group, a Cat to C6 alkoxy group or an amino group, and R3 is a hydrogen atom or a C' to C6 alkyl group. Cat to C6 alkenyl, C' to C6 alkynyl or Cal to C6 aminoalkyl group or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of Q fever.
20. Use according to Claim 19, in which Rt is a hydrogen atom and R2 is a methoxy group.
21. Use according to Claim 19 or Claim 20, in which R3 is a Cal to C6 aminoalkyl group.
22. Use according to Claim 21, in which R3 is art aminomethyl group.
23. Use according to any of Claims 19 to 22, in which the compound comprises the S stereoisomer.
24. A method of treatment of Q fever and other rickettsia infections comprising the step of administering to a patient in need thereof a pharmaceutically effective amount of a compound of formula (II) (II) in which Rt is hydrogen atom or a C' to C6 alkyl group, R2 is a hydroxyl group, a C' to C6 alkoxy group or an amino group, and R3 is a hydrogen atom or a Cal to C6 alkyl, C' to C6 alkenyl, Cat to C6 alkynyl Cal to C6 aminoalkyl group or a pharmaceutically acceptable salt thereof.
25. A method according to Claim 24, in which Rat is a hydrogen atom and R2 is a methoxy group.
26. A method according to Claim 24 or Claim 25, in which R3 is a Cat to C6 aminoalkyl group.
27. A method according to Claim 26, in which R3 is an aminomethyl group.
28. A method according to any of Claims 24 to 27, in which the compound comprises the S stereoisomer.
29. A pharmaceutical composition for the treatment of Q fever and other rickettsia infections comprising a pharmaceutically effective amount of a compound of formula (II) 1 to Rip BILL (II) in which Ret is hydrogen atom or a Cat to C6 alkyl group, R2 is a hydroxyl group, a Cat to C6 alkoxy group or an amino group, and R3 is a hydrogen atom or a Cat to C6 alkyl, C, to C6 alkenyl, Cal to C6 alkynyl or Cat to C6 aminoalkyl group or a pharmaceutically acceptable salt thereof.
30. A composition according to Claim 29, in which R' is a hydrogen atom and R2 is a methoxy group.
31. A composition according to Claim 29 or Claim 30, in which R3 is a Cal to C6 aminoalkyl group.
32. A composition according to Claim 31, in which R3 is an aminomethyl group.
33. A composition according to any of Claims 29 to 32, in which the compound comprises the S stereoisomer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0307262A GB2400033A (en) | 2003-03-29 | 2003-03-29 | Use of fluoroquinolone antibiotics for the treatment of Q fever |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0307262A GB2400033A (en) | 2003-03-29 | 2003-03-29 | Use of fluoroquinolone antibiotics for the treatment of Q fever |
Publications (2)
Publication Number | Publication Date |
---|---|
GB0307262D0 GB0307262D0 (en) | 2003-05-07 |
GB2400033A true GB2400033A (en) | 2004-10-06 |
Family
ID=9955780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB0307262A Withdrawn GB2400033A (en) | 2003-03-29 | 2003-03-29 | Use of fluoroquinolone antibiotics for the treatment of Q fever |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2400033A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002013830A1 (en) * | 2000-08-14 | 2002-02-21 | Senju Pharmaceutical Co., Ltd. | Cytokine production inhibitors |
-
2003
- 2003-03-29 GB GB0307262A patent/GB2400033A/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002013830A1 (en) * | 2000-08-14 | 2002-02-21 | Senju Pharmaceutical Co., Ltd. | Cytokine production inhibitors |
EP1312364A1 (en) * | 2000-08-14 | 2003-05-21 | Senju Pharmaceutical Co., Ltd. | Cytokine production inhibitors |
Non-Patent Citations (4)
Title |
---|
CAS Abstract No. 128:57114 & Clinical Therapeutics, Vol. 19, No. 5, 1997, (STUART TOPKIS et al), pages 975-988. * |
CAS Abstract No. 129:12188 & Clinical Microbiology and Infection, Vol. 4 Suppl. 1, 1998, (SANFORD CHODOSH), pages S25-S31. * |
CAS Abstract No. 131:317375 & Chest, Vol. 116, No. 4, 1999, (MOOLA S. et al), pages 974-983. * |
CAS Abstract No. 131:39045 & Expert Opinion on Investigational Drugs, Vol. 8, No. 4, 1999, (ALASDAIR M. GEDDES), pages 487-505. * |
Also Published As
Publication number | Publication date |
---|---|
GB0307262D0 (en) | 2003-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9314456B2 (en) | Antibacterial compounds | |
KR101413997B1 (en) | Quinoline derivatives as antibacterial agents | |
WO2011005355A1 (en) | Combinations comprising a lpxc inhibitor and an antibiotic for use in the treatment of infections caused by gram-negative bacteria | |
IL179630A (en) | Use of substituted quinoline derivatives for the preparation of medicaments for the treatment of drug resistant mycobacterial diseases | |
JP2007502861A (en) | Antibacterial methods and compositions | |
KR101334719B1 (en) | Antibacterial quinoline derivatives | |
US20150209340A1 (en) | Compounds for the treatment of clostridium difficile associated disease | |
KR101329587B1 (en) | Quinoline derivatives as antibacterial agents | |
KR20080039961A (en) | Quinoline derivatives as antibacterial agents | |
US20100113430A1 (en) | Thioxanthene derivates useful to treat infectious diseases | |
KR20110050623A (en) | Antibiotic drug | |
MX2013005561A (en) | Methods of treating eye diseases associated with inflammation and vascular proliferation. | |
JP2014240401A (en) | Thioxanthene derivatives for the treatment of infectious diseases | |
KR101490221B1 (en) | Antibacterial quinoline derivatives | |
GB2400033A (en) | Use of fluoroquinolone antibiotics for the treatment of Q fever | |
WO2011151619A1 (en) | Compounds for the treatment of clostridium difficile associated disease | |
JP5349730B2 (en) | Quinoline derivatives as antibacterial agents | |
JPH07215861A (en) | Method for increasing function of macrophage | |
WO2021250635A1 (en) | Acid salts of fluoroquinolone carboxylic acid based compositions and methods of making and using the same | |
KR20210009477A (en) | Anti-methicillin resistant staphylococcus aureus compound and its medical use | |
HUT77379A (en) | Use of azaspirane derivatives for treating accustomed infections | |
GB2403653A (en) | Use of fluoroquinone antibiotics for the treatment of plague |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |